Mitumomab
Mitumomab
Mitumomab (pronunciation: /miːˈtjuːmoʊmæb/) is a type of monoclonal antibody used in cancer treatment.
Etymology
The term "Mitumomab" is derived from the Latin "mitum", meaning "to send", and the Greek "mab", meaning "antibody". This reflects the drug's function as a targeted therapy, sent to attack specific cancer cells.
Usage
Mitumomab is used in the treatment of various types of cancer, including colorectal cancer, ovarian cancer, and lung cancer. It works by binding to specific proteins on the surface of cancer cells, thereby marking them for destruction by the body's immune system.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Cancer: A group of diseases characterized by the uncontrolled growth and spread of abnormal cells.
- Colorectal cancer: A cancer that starts in the colon or the rectum.
- Ovarian cancer: A type of cancer that begins in the ovaries.
- Lung cancer: A type of cancer that begins in the lungs.
See Also
External links
- Medical encyclopedia article on Mitumomab
- Wikipedia's article - Mitumomab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski